SecSonar.com

ImmuCell Corporation (ICCC)

ImmuCell Corporation at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

ImmuCell Corporation (ICCC) is a Biotechnology company based in US with a market capitalization of $89.6M. Revenue grew 4.3% year-over-year and the company generated $1.2M in free cash flow. This page tracks ICCC's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 69 employees · IPO May 5, 1987

Valuation

Valuation & price

$8.92 · as of May 17, 2026 · -18.9% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

3.31

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$10.29$7.42$4.56Jul 25Dec 25Jul 26Jul 7, 25$6.54Jul 9, 25$6.75Jul 11, 25$6.48Jul 15, 25$6.26Jul 17, 25$6.60Jul 21, 25$6.82Jul 23, 25$6.95Jul 25, 25$6.61Jul 29, 25$6.49Jul 31, 25$6.37Aug 4, 25$6.25Aug 6, 25$6.18Aug 11, 25$6.66Aug 13, 25$6.53Aug 15, 25$6.10Aug 19, 25$5.90Aug 21, 25$5.98Aug 25, 25$6.09Aug 27, 25$6.10Aug 29, 25$6.40Sep 3, 25$6.53Sep 5, 25$6.33Sep 9, 25$6.16Sep 11, 25$6.13Sep 16, 25$5.90Sep 18, 25$5.66Sep 22, 25$6.25Sep 24, 25$6.06Sep 26, 25$6.03Sep 30, 25$6.25Oct 2, 25$6.55Oct 6, 25$6.35Oct 8, 25$6.59Oct 10, 25$6.80Oct 14, 25$6.52Oct 16, 25$6.25Oct 21, 25$6.13Oct 23, 25$6.06Oct 27, 25$6.24Oct 29, 25$6.03Oct 31, 25$6.24Nov 4, 25$6.00Nov 6, 25$6.31Nov 10, 25$6.08Nov 12, 25$6.13Nov 14, 25$5.40Nov 18, 25$4.56Nov 20, 25$4.60Nov 25, 25$4.68Nov 28, 25$4.84Dec 2, 25$5.00Dec 4, 25$5.21Dec 8, 25$5.48Dec 10, 25$5.87Dec 12, 25$6.21Dec 16, 25$6.04Dec 18, 25$6.14Dec 22, 25$5.90Dec 24, 25$5.80Dec 29, 25$6.15Jan 2, 26$5.92Jan 6, 26$6.35Jan 8, 26$6.57Jan 12, 26$6.67Jan 14, 26$6.62Jan 16, 26$6.36Jan 21, 26$6.80Jan 23, 26$6.26Jan 27, 26$6.27Jan 29, 26$6.04Feb 2, 26$6.11Feb 4, 26$6.07Feb 9, 26$6.64Feb 11, 26$6.49Feb 13, 26$6.60Feb 18, 26$6.48Feb 20, 26$6.42Feb 24, 26$6.56Feb 26, 26$6.55Mar 2, 26$6.54Mar 4, 26$6.46Mar 6, 26$6.60Mar 10, 26$6.63Mar 12, 26$6.63Mar 17, 26$6.05Mar 19, 26$6.15Mar 23, 26$6.41Mar 25, 26$6.44Mar 27, 26$6.52Mar 31, 26$6.33Apr 2, 26$6.44Apr 7, 26$6.60Apr 9, 26$7.19Apr 13, 26$7.11Apr 15, 26$7.60Apr 17, 26$7.98Apr 22, 26$7.82Apr 24, 26$8.36Apr 28, 26$8.35Apr 30, 26$8.46May 4, 26$8.72May 6, 26$8.66May 8, 26$8.05May 12, 26$8.38May 14, 26$8.26May 18, 26$9.91May 20, 26$9.88May 22, 26$10.12May 28, 26$9.90Jun 1, 26$9.67Jun 3, 26$10.05Jun 5, 26$9.61Jun 9, 26$9.77Jun 11, 26$9.74Jun 15, 26$9.53Jun 17, 26$9.39Jun 22, 26$9.74Jun 24, 26$9.79Jun 26, 26$9.79Jul 2, 26$10.29
$4.5652-week range$11.00
Loading valuation history…

Fundamentals

Key fundamentals

$89.6M

Market cap

4.3%

Revenue growth (YoY)

41.4%

Gross margin

$1.2M

Free cash flow (USD)

$9.4M

Net debt

10.5%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$9.5MFY 2017$10.4MFY 2018$11.0MFY 2019$13.7MFY 2020$15.3MFY 2021$19.2MFY 2022$18.6MFY 2023$17.5MFY 2024$26.5MFY 2025$27.6M
$9.5M$27.6M

Free cash flow by year

2016 → 2025

FY 2016$-3.9MFY 2017$-16.6MFY 2018$-2.4MFY 2019$-1.2MFY 2020$-2.8MFY 2021$-1.7MFY 2022$-5.5MFY 2023$-6.6MFY 2024$-107.8KFY 2025$1.2M
-$3.9M$1.2M

Gross margin by year

2021 → 2025

FY 202145.0%FY 202241.2%FY 202325.2%FY 202430.0%FY 202541.4%
45.0%41.4%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last reported: May 14, 2026 (EPS $0.21)

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 17, 2026Filing
  • 8-K eventManufacturing Capacity ExpansionJun 10, 2026Filing
  • Quarterly report10-Q FiledMay 14, 2026Filing
  • 8-K eventEarnings ReleaseMay 14, 2026Filing
  • Annual report10-K FiledMay 13, 2026Filing
  • 8-K eventSettlement AgreementMay 8, 2026Filing
  • 8-K eventBoard ChangesApr 14, 2026Filing
  • 8-K eventEarnings ReleaseApr 8, 2026Filing

Questions

Frequently asked questions

What is ImmuCell Corporation's market cap?

ImmuCell Corporation (ICCC) has a market capitalization of $89.6M.

What is ICCC's P/E ratio?

A meaningful P/E ratio is not available for ICCC — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is ICCC's price-to-book (P/B) ratio?

ICCC trades at 3.31 times book value per share.

When did ImmuCell Corporation last report earnings?

ICCC last reported earnings on May 14, 2026; the next date is not yet scheduled.

Are insiders buying ICCC stock?

SEC Form 4 filings show no open-market insider buys at ImmuCell Corporation in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

DTIL

Precision BioSciences, Inc.

$89.5M

NRXS

NeurAxis, Inc.

$89.9M

ANIX

Anixa Biosciences, Inc.

$92.2M

VTVT

vTv Therapeutics Inc.

$86.7M

COYA

Coya Therapeutics, Inc.

$86.3M

FBIO

Fortress Biotech, Inc.

$93.3M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.